Paper10691586
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Vadhan-Raj S and 10 others. Ann Intern Med, 2000. Cited by 140 papers, by iCite.
Cite this record
ConductScience Library. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Papers, record 10691586. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10691586
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
- PubMed
- Publication types
- Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carboplatin | Major topic |
| Genital Neoplasms, Female | Major topic |
| Thrombocytopenia | Major topic |
| Thrombopoietin | Major topic |
| Analysis of Variance | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Platelet Count | |
| Platelet Transfusion | |
| Recombinant Proteins |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 HL53586 | NHLBI NIH HHS | United States | P01HL053586 | PubMed and NIH | NIH RePORTER |
| R01 HL54037 | NHLBI NIH HHS | United States | R01HL054037 | PubMed and NIH | NIH RePORTER |
| R01 HL56416 | NHLBI NIH HHS | United States | R01HL056416 | PubMed and NIH | NIH RePORTER |
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42854051 | Single-center experience with Romiplostim N01 for the management of severe persistent cancer therapy-induced thrombocytopenia in lung cancer: Insights and outcomes. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/42854051 | PubMed |
| 42658302 | Efficacy and clinical outcomes of proximal splenic artery embolization in patients with chemotherapy induced thrombocytopenia. | Langenbecks Arch Surg | 2026 | https://conductscience.org/library/papers/42658302 | PubMed |
| 42222375 | Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods. | Front Oncol | 2026 | https://conductscience.org/library/papers/42222375 | PubMed |
| 41932340 | Dietary restriction mitigates 5-fluorouracil-induced thrombocytopenia in aged mice via mitochondrial potentiation in hematopoietic stem cells and megakaryocyte progenitors. | Stem Cell Reports | 2026 | https://conductscience.org/library/papers/41932340 | PubMed |
| 41629833 | Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41629833 | PubMed |
| 41063990 | Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management. | Front Immunol | 2025 | https://conductscience.org/library/papers/41063990 | PubMed |
| 40904833 | A nomogram for predicting the risk of chemoradiotherapy-associated thrombocytopenia in patients with esophageal cancer: a real-world cohort study. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/40904833 | PubMed |
| 40003683 | Thrombocytopenia in Sepsis. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40003683 | PubMed |
| 39495281 | Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia. | Ann Hematol | 2024 | https://conductscience.org/library/papers/39495281 | PubMed |
| 38077816 | Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors. | Res Pract Thromb Haemost | 2023 | https://conductscience.org/library/papers/38077816 | PubMed |
| 37749031 | [Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/37749031 | PubMed |
| 37259024 | Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37259024 | PubMed |
| 37039010 | Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia. | Expert Rev Hematol | 2023 | https://conductscience.org/library/papers/37039010 | PubMed |
| 36865986 | Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia. | Ther Adv Hematol | 2023 | https://conductscience.org/library/papers/36865986 | PubMed |
| 36695938 | Chemotherapy-induced thrombocytopenia: literature review. | Discov Oncol | 2023 | https://conductscience.org/library/papers/36695938 | PubMed |
| 36485134 | Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. | Hematology Am Soc Hematol Educ Program | 2022 | https://conductscience.org/library/papers/36485134 | PubMed |
| 36430539 | A Novel Antithrombocytopenia Agent, Rhizoma cibotii, Promotes Megakaryopoiesis and Thrombopoiesis through the PI3K/AKT, MEK/ERK, and JAK2/STAT3 Signaling Pathways. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430539 | PubMed |
| 35679540 | Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia. | PLoS One | 2022 | https://conductscience.org/library/papers/35679540 | PubMed |
| 35642485 | Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. | Haematologica | 2022 | https://conductscience.org/library/papers/35642485 | PubMed |
| 35554955 | Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial. | Hematol Oncol | 2022 | https://conductscience.org/library/papers/35554955 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| THPO | 7066 | PubTator's text mining | https://conductscience.org/library/genes/7066 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10691586
GET https://conductscience.org/api/papers/v1/10691586/cited_by?page=2